FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of Spravato, granted following FDA priority review, was based on the results of a ... Read More

FDA approves nasal spray drug to treat depression - ConsumerAffairs

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved the nasal spray Spravato as a treatment for severe depression. Read More

FDA approves first nasal spray for major depression disorder

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive disorder. Read More

Hope for Depression and Other Diagnoses with Psychedelics

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable depression. The HHS and FDA voice support for psychedelics. Read More

FDA approves first nasal spray treatment for severe depression - MSN

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment ... Read More

Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent ...

Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD) with inadequate response to at least 2 oral antidepressants. Read More

FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant ...

Spravato is the first and only monotherapy to gain FDA approval for treatment-resistant depression. Read More

FDA approves 1st monotherapy drug for treatment-resistant depression ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression. The approval follows a priority review and is ... Read More

FDA Approves Johnson & Johnson's Treatment As First ... - Benzinga

FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials. Read More

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ... Read More